Genprex, Inc.
GNPX evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for GNPX—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · GNPX
Genprex, Inc. is a clinical-stage biotechnology company developing gene therapies for oncology and diabetes, with a lead candidate reqorsa in Phase 2 trials and a diabetes gene therapy program in preclinical development.
Key risk: Going concern risk
BioSniper Score
Based on 6 of 6 signals
Market Cap
$3.0M
Cash Runway
9.0 moLead Asset
gpx-002 (Preclinical)
Next Catalyst
Phase2_Topline · Dec 31, 2026Financial data as of Jun 30, 2026.
Tracking 2 pipeline candidates · 3 clinical trials · 2 catalysts for Genprex, Inc..
Genprex, Inc. is a clinical-stage biotechnology company developing gene therapies for oncology and diabetes, with a lead candidate reqorsa in Phase 2 trials and a diabetes gene therapy program in preclinical development.
- Lead product candidate reqorsa is being evaluated in Phase 2 clinical trials for non-small cell lung cancer [sec_mda · as of 2026-08-14].
- Diabetes gene therapy program is in preclinical development; the company met with the FDA in February 2026 to discuss IND-enabling studies [sec_mda · as of 2026-08-14].
- Cash and cash equivalents were $15.2 million as of June 30, 2026 [sec_mda · as of 2026-08-14].
- Net income for the quarter ended June 30, 2026 was -$4.4 million [latest reported financials as of 2026-06-30].
- The company has raised capital through an ATM facility, with approximately $58.6 million remaining unsold as of March 2026 [sec_mda · as of 2026-03-30].
What works
- Genprex has a diversified pipeline targeting both oncology (reqorsa) and diabetes (gene therapy), which may reduce program-specific risk [sec_mda · as of 2026-08-14].
- The company has engaged with the FDA for its diabetes gene therapy program, receiving feedback that aligned with its plans, indicating regulatory progress [sec_mda · as of 2026-08-14].
- Genprex has access to additional capital through its ATM facility, with $58.6 million in unsold shares as of March 2026, providing potential funding flexibility [sec_mda · as of 2026-03-30].
What to weigh
- The company has no approved products and does not expect to generate revenue from product sales unless and until it completes development and obtains regulatory approval [sec_mda · as of 2026-03-30].
- Genprex has experienced delays in clinical trial enrollment due to competition for patients and manufacturing transitions, which could consume capital without advancing trials [sec_mda · as of 2026-03-30].
- The company has expressed substantial doubt about its ability to continue as a going concern, noting insufficient cash to cover requirements through fiscal year 2027 without additional financing [sec_mda · as of 2026-03-30].
- Genprex may be unable to raise additional funds on favorable terms, which could force it to delay, limit, or terminate research and development programs [sec_mda · as of 2026-08-14].
From the filings
Quoted directly from source documents.
Lead candidate reqorsa is in Phase 2 trials for non-small cell lung cancer.
“payment obligations associated with our ongoing conduct and monitoring of our Acclaim clinical trials”
SEC MD&A · March 30, 2026
Cash position as of June 30, 2026.
“As of June 30, 2026, we had $15,154,203 in cash and cash equivalents.”
SEC MD&A · August 14, 2026
FDA meeting for diabetes gene therapy program.
“On February 19, 2026, we met with the FDA and received feedback which we believe aligned with our expectations and plans.”
SEC MD&A · August 14, 2026
Going concern uncertainty.
“The foregoing conditions raise substantial doubt regarding our ability to continue as a going concern for a period of one year after the date the consolidated financial statements included in this Annual Report are issued.”
SEC MD&A · March 30, 2026
Catalyst timeline
- 2026-12-31 · Phase2_Topline · reqorsa — Phase 2 Readout: reqorsa — Topline data from the Phase 2 trial of reqorsa is expected, which could inform the program's viability and next steps.
- 2027-06-30 · Phase2_Topline · reqorsa — Phase 2 Readout: reqorsa — A second Phase 2 readout for reqorsa is anticipated, providing further data on efficacy and safety.
Risks & what to watch (4)›
Key risks
- Going concern risk — Substantial doubt about ability to continue as a going concern; insufficient cash through fiscal 2027 without additional financing [sec_mda · as of 2026-03-30].
- Clinical trial delays — Delays in enrollment due to patient competition and manufacturing transitions may consume capital without advancing trials [sec_mda · as of 2026-03-30].
- Dependence on future funding — May be unable to raise additional funds on favorable terms, potentially forcing program delays or termination [sec_mda · as of 2026-08-14].
- No approved products — No revenue from product sales expected until successful development and regulatory approval [sec_mda · as of 2026-03-30].
What to watch
- Phase 2 topline data for reqorsa expected by end of 2026 [upcoming catalysts].
- Progress of diabetes gene therapy program, including IND-enabling studies and potential clinical trial initiation [sec_mda · as of 2026-08-14].
- Cash runway and ability to raise additional capital through ATM facility or other means [sec_mda · as of 2026-08-14].
- Any strategic restructuring or prioritization of pipeline programs [sec_mda · as of 2026-08-14].
Sources: SEC MD&A · Generated August 29, 2026 · How we verify sources →
Run Genprex, Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Genprex, Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 6 of 6 signals · derived from public data
9.0 months
D/E 0.16
Lead: Phase 2
2 candidates
2 upcoming, next in ~123d
0 buys · 2 sells (180d)
Runway
Catalysts
Pipeline
Regulatory
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
21
Total value held
$127K
| Holder | Shares | Value |
|---|---|---|
| geode capital management, llc | 33,372 | $60K |
| manchester financial inc | 20,000 | $36K |
| vanguard capital management llc | 11,900 | $22K |
| jones financial companies lllp | 2,105 | $4K |
| citigroup inc | 2,039 | $4K |
| osaic holdings, inc. | 232 | $417 |
| blackrock, inc. | 188 | $340 |
| harbour investments, inc. | 120 | $218 |
| sbi securities co., ltd. | 48 | $87 |
| highmark wealth management llc | 10 | $18 |
Showing top 10 of 21 institutional holders of Genprex, Inc.. Open the full 13F history after sign-in.
Short Interest
as of May 21, 2026- % of float
- 10.8%
- Days to cover
- 1.0
- Shares short
- 1,121,624
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
GNPX short interestGovernance
Frequently asked questions
What is the AI investment thesis for Genprex, Inc.?
Genprex, Inc. is a clinical-stage biotechnology company developing gene therapies for oncology and diabetes, with a lead candidate reqorsa in Phase 2 trials and a diabetes gene therapy program in preclinical development.
What is Genprex, Inc.'s lead drug candidate?
Genprex, Inc.'s most advanced tracked candidate is gpx-002 (Preclinical) for Type 1 diabetes and Type 2 diabetes.
What is Genprex, Inc.'s next catalyst?
Genprex, Inc.'s next tracked catalyst is a Phase2_Topline event — "Phase 2 Readout: reqorsa" — expected December 31, 2026.
Who is the CEO of Genprex, Inc.?
Mr. Ryan M. Confer M.S. is the chief executive officer of Genprex, Inc. (GNPX).
Where is Genprex, Inc. headquartered?
Genprex, Inc. (GNPX) is headquartered in Austin, TX, United States.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.